Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: July 31, 2006
Last updated: September 13, 2007
Last verified: September 2007

Methods study to evaluate use of cardiac ultrasound to assess heart valve abnormality in people.

Condition Intervention
Heart Valve Diseases
Device: cardiac echosonography

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: A Randomized, Open-Label, Methodology Trial To Investigate The Utility Of Echocardiography In Assessment Of Cardiac Valvular Regurgitation In Adult Subjects

Resource links provided by NLM:

Further study details as provided by Pfizer:

Estimated Enrollment: 30
Study Start Date: April 2007
Study Completion Date: July 2007

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • >=18 years of age subjects with stable concomitant diseases with BMI >=30 kg/m2

Exclusion Criteria:

  • Pregnant females
  • Those with unstable/new onset diseases
  • Those who are on agents known to be associated with cardiac valvular heart disease
  Contacts and Locations
Please refer to this study by its identifier: NCT00359489

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511-5473
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided Identifier: NCT00359489     History of Changes
Other Study ID Numbers: A9001336
Study First Received: July 31, 2006
Last Updated: September 13, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases processed this record on April 17, 2014